论文部分内容阅读
大部分原发性肝癌确诊时已接近晚期 ,80 %不能手术切除 ,由于肝癌主要由肝动脉供血 ,经皮肝动脉栓塞化疗 (ＴＡＣＥ)已成为不宜手术切除病例的主要治疗手段。羟基喜树碱 (ＨＣＰＴ)为珙桐科植物喜树中提取的一类选择性抑制拓扑异构酶Ｉ (ＴＯＰＩ)的抗癌药 ,通过抑制ＴＯＰＩ,?
Most of the primary liver cancer is nearing the end of its diagnosis, and 80% of the patients can not be surgically resected. As liver cancer is mainly supplied by the hepatic artery, percutaneous transhepatic arterial chemoembolization (TACE) has become the main treatment for patients who are not suitable for surgical resection. Hydroxycamptothecin (HCPT) is a class of anti-cancer drugs that selectively inhibit topoisomerase I (TOPI) extracted from Camptotheca acuminatum. By inhibiting TOPI,